Compare DoorDash Inc (DASH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs TG Therapeutics Inc — how do they compare? DoorDash Inc trades at $197.5 (market cap $83.07B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: DoorDash Inc is far larger — about 10.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and TG Therapeutics Inc for 16 Days on average.
| DASH | TGTX | |
|---|---|---|
Market Cap | $83.07B | $8.16B |
Volume | 3,242,567 | 1,735,121 |
Sector | Media | Health |
52-Week High | $275.44 | $59.06 |
52-Week Low | $146.60 | $26.94 |
Typical Hold Time | 59 Days | 16 Days |
Enterprise Value | $81.03B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $196.50, up 2.75% with a bullish technical outlook supported by moving averages. The company shows strong revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with $935M net income. Recent innovations include AI text ordering and drone delivery expansion. Analyst consensus remains strongly bullish with a $255.80 price target, though valuation metrics appear elevated with P/E at 100.37.
The outlook remains positive with continued revenue growth projected to $15.9B in 2026 and expanding market opportunities. Key risks include competitive pressures, regulatory scrutiny from ongoing investigations, and high valuation multiples. The stock offers growth potential but requires monitoring of execution risks and margin sustainability amid aggressive expansion initiatives.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
